IPLESP at the forefront of COVID-19 research
From January 2020, several IPLESP teams have initiated research on the new coronavirus in different areas: modelling, surveillance, population epidemiology, clinical epidemiology, therapeutic evaluation, social epidemiology. This work gave rise to fruitful collaborations between the teams and their results were communicated during online seminars (https://youtu.be/ieKOlo-DXvA , https://youtu.be/zuw3u1QS90M).
Team SUMO has developed a suite of models to tackle different aspects of the COVID-19 pandemic: risk analysis of healthcare systems, analysis of case importations on the French territory, and the development of scenarios for mitigation and lockdown exit. The Sentinelles network provide important data for monitoring the spread of the new coronavirus in France. Future work will focus on the analysis of seroprevalence data and numerical approaches for mobility tracing and contact reduction.
Team CLEPIVIR co-leads the SAPRIS study involving the collection of clinical and serological data on 130,000 participants included in the French general population cohorts (Constances, E3N-E4N, NutriNet Santé, Elfe Epipage 2). The team also evaluates the impact of the epidemic on hospitalization using medico-administrative data and coordinates the CORIPLASM clinical trial to assess the efficacy of hyperimmune plasma. Its future work will focus on the description and prognosis of persistent forms of COVID-19 and the prediction of severe forms of COVID-19 from hospital data warehouses.
Team THERAVIR has evaluated the effectiveness of drugs targeting COVID-19 in collaboration with the PEPITES team and has developed virological tools to study this infection (measurement of the neutralizing activity of antibodies, analysis of molecular epidemiology). It is involved in a cohort of SARS-CoV-2 infected persons followed-up on an outpatient basis. Its future work will focus on the analysis of seroprevalence and serum neutralization data. It will also actively contribute to the adaptive, multinational and pan-European clinical trial platform for COVID-19 and other emerging infectious diseases (DisCoVeRy for Solidarity). Finally, it will coordinate the FAMICOV study, on the evaluation of intra-household transmission of SARS-CoV-2 infection.
Team EPAR is working on SARS-COV-2 airborne transmission, the relationships between air pollution exposure and COVID-19 severity and fatality and the impact of lockdown air pollution decline on COVID-19 at the national and international level. These works are conducted in collaboration with the European Respiratory Society (ERS) and the American Thoracic Society (ATS).
Team PEPITES is involved in several patient cohort studies (COVID ICU, COVIDeF, COACH, COVIDOM, SEROCOV) which will help to better understand the natural history of the disease, to identify risk and prognostic factors and to study the evolution of seroprevalence among caregivers. The COVIMID project, based on the national healthcare database, will assess the impact of the pandemic on patients with chronic inflammatory diseases. Finally, the team has designed and implemented several clinical trials in prophylaxis (revaccination by BCG, nicotine patches) or treatment (Hydroxychloroquine in general medicine, Nivolumab, Nicotine).
Team ERES is conducting research on the impact of the COVID-19 epidemic in terms of social inequalities, mental health and addictive behaviour, through studies in the general population (COMET international study, TEMPO cohort) and among people in precarious situations (ECHO study). It is also taking part in a randomised controlled trial on the effectiveness of Hydroxychloroquine in primary care (MG-COVID) as well as in qualitative research aiming to describe the health of special populations (e.g. EPIC project conducted among pregnant women).